{'fraction_non_alphanumeric': 0.04377880184331797, 'fraction_numerical': 0.04377880184331797, 'mean_word_length': 5.034722222222222, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B‐cell lymphoma/leukaemia: a Children's Oncology Group report

The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French‐American‐British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B‐cell lymphoma/leukaemia. Patients received rituximab (375 mg/m2) days −2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group‐B); 245 ± 31 and 321 ± 32 μg/ml (Group‐C)] with sustained troughs and t½ of 26–29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t½.